GPT and Fever: Despite this limitation, notable differences in the rates of the common AEs were identified, including relatively higher rates of diarrhea, arthralgia, rash, photosensitivity reaction, and increased alanine aminotransferase (ALT) with vemurafenib/cobimetinib; higher rates of pyrexia, hypertension, cough, and chills with dabrafenib/trametinib; and a higher rate elevated blood creatine phosphokinase with encorafenib/binimetinib (see Table S2, which presents AEs in ≥20% of patients in any combination treatment arm).